RE:RE:Just thinking out loud.... gpe2005 wrote: In my opinion, SZLS has not been able to show the ability to sell their product. ColonSentry has been on the market for some time now with very little success. Mercer has been supporting the COVID testing but till sending thier cancer clients to ColonSentry's competitors. The idea that single cancer testing is being held back waiting for Aristotle holds no water. That's like when Apple came out with the first I Phone, Steve saying "let's wait till next year when we have the next generation I Phone". Why they can't seem to get ColonSentry off the ground is another question.
Colon Sentry was launched at a time of doubt in the product`s ability to be successful . As of late, liquid biopsies are gaining ground. Why? In Aristotle, Colon Sentry has merged into it with amendments. Aristotle is able to detect for example polyps in the colon on the loeft, or right side , the right being deadly. Liquid biopsies are just coming to light now, in that they ae able to detect, pinpoint, and rule stage 1,2,3 or 4 and where in the body it came from, without invasive techniques. Insurance companies would much rather pay for a blood test , than an endoscopy, and this all being in the case of colon. Add another 9 including the deadly pancreatic cancer.
AstraZeneca and
Merck are 2 entities that support this technique moving forward.
Link Here
Liquid Biopsies More Info